Update medical terms cache

data/medical_terms_cache.json

@@ -4,21 +4,21 @@
       "esmo"
     ],
     "esmo": [
-      "european society of medical oncology",
-      "european society for\nmedical oncology",
+      "european\nsociety of medical oncology",
       "the european society for medical oncology",
       "the european society for medical\noncology",
-      "european\nsociety of medical oncology",
-      "european society for medical oncology"
+      "european society for medical oncology",
+      "european society for\nmedical oncology",
+      "european society of medical oncology"
     ],
     "american society of clinical\n\noncology": [
       "asco"
     ],
     "asco": [
+      "inc",
       "american\nsociety of clinical oncology",
       "american society of clinical\n\noncology",
       "md american society of clinical oncology",
-      "inc",
       "american society of clinical oncology"
     ],
     "italian association of medical oncology": [
@@ -32,27 +32,27 @@
       "nccn"
     ],
     "nccn": [
-      "leading american cancer centers",
       "vs insurance-based",
+      "leading american cancer centers",
       "national comprehensive cancer network"
     ],
     "non-small cell lung cancer": [
       "nsclc"
     ],
     "nsclc": [
-      "non-small cell lung cancer",
-      "robotic lobectomy for non-small cell lung cancer",
-      "advanced non-small-cell lung cancer",
-      "small-cell lung cancer",
       "non-small-cell lung cancer",
       "advanced non-small cell lung cancer",
+      "cancer",
+      "mutant advanced non-small cell lung cancer",
       "stage iii non small cell lung cancer",
       "small cell\nlung cancer",
-      "mutant advanced non-small cell lung cancer",
       "iii non-small-cell lung cancer",
+      "advanced non-small-cell lung cancer",
       "small-cell\nlung cancer",
       "lung cancer",
-      "cancer"
+      "small-cell lung cancer",
+      "robotic lobectomy for non-small cell lung cancer",
+      "non-small cell lung cancer"
     ],
     "american\nsociety of clinical oncology": [
       "asco"
@@ -77,9 +77,9 @@
       "ema"
     ],
     "ema": [
-      "european medicines agency",
       "and the european medicines\nagency",
       "for all the newly\neuropean medicines agency",
+      "european medicines agency",
       "not european medicines agency"
     ],
     "evaluates treatments with curative intent": [
@@ -138,9 +138,9 @@
       "rcts"
     ],
     "rcts": [
-      "two randomized control trials",
       "controlled trials",
-      "clinical trials"
+      "clinical trials",
+      "two randomized control trials"
     ],
     "the primary end point was disease-free\nsurvival": [
       "dfs"
@@ -161,72 +161,72 @@
       "inst"
     ],
     "inst": [
-      "mirati therapeutics",
-      "bms",
-      "genentech",
-      "abbvie",
+      "sutro biopharma",
+      "amgen",
+      "roche",
       "merck",
+      "crispr\ntherapeutics",
+      "constellation pharmaceuticals",
+      "bristol-myers squibb",
+      "nuvation bio",
+      "calithera biosciences",
+      "genentech",
+      "gsk",
+      "astex pharmaceuticals",
+      "merck serono",
+      "vivace therapeutics",
+      "neogenomics",
+      "novartis",
+      "elevation oncology",
+      "advaxis",
       "glaxosmithkline",
-      "forward",
-      "oncomed",
-      "bayer",
-      "revolution medicines",
-      "puma biotechnology",
-      "guardant health",
+      "bms",
+      "summit therapeutics",
+      "takeda",
+      "blueprint medicines",
+      "pharmamar",
+      "astrazeneca canada",
       "turning point therapeutics",
-      "oric pharmaceuticals",
-      "trizell",
-      "exelixis",
-      "msd",
+      "janssen",
       "glaxosmithkline canada",
-      "bristol-myers squibb",
-      "harpoon therapeutics",
+      "inc",
+      "abbvie",
+      "pfizer",
+      "polaris",
+      "exelixis",
       "macrogenics",
+      "bristol myers squibb foundation",
+      "astrazeneca",
+      "oric pharmaceuticals",
+      "mirati therapeutics",
+      "puma biotechnology",
+      "palobiofarma",
       "anheart therapeutics",
-      "roche",
-      "pfizer",
-      "dohme",
+      "harpoon therapeutics",
+      "boehringer ingelheim",
       "cullinan oncology",
-      "janssen oncology",
-      "calithera biosciences",
-      "jazz pharmaceuticals",
+      "trizell",
       "medimmune",
       "arcus biosciences",
-      "bristol myers squibb foundation",
-      "janssen",
-      "elevation oncology",
       "lilly",
-      "takeda",
-      "astra zeneca",
-      "astrazeneca canada",
       "therapeutics",
-      "sutro biopharma",
-      "inhibrx",
-      "vivace therapeutics",
-      "regeneron",
-      "gsk",
-      "merck serono",
-      "palobiofarma",
-      "boehringer ingelheim",
-      "constellation pharmaceuticals",
-      "astex pharmaceuticals",
-      "verastem",
+      "oncomed",
       "black diamond\ntherapeutics",
-      "summit therapeutics",
-      "amgen",
+      "janssen oncology",
+      "jazz pharmaceuticals",
+      "astra zeneca",
       "dizal\npharma",
-      "novartis",
-      "blueprint medicines",
-      "nuvation bio",
+      "msd",
       "bristol myers squibb",
-      "pharmamar",
-      "advaxis",
-      "crispr\ntherapeutics",
-      "astrazeneca",
+      "dohme",
+      "regeneron",
+      "inhibrx",
+      "guardant health",
+      "verastem",
       "bristol myers\nsquibb",
-      "inc",
-      "neogenomics",
-      "polaris"
+      "revolution medicines",
+      "forward",
+      "bayer"
     ],
     "pfizer": [
       "inst"
@@ -247,17 +247,17 @@
       "of patients with\nstage i to iii sclc"
     ],
     "small-cell lung cancer": [
-      "nsclc",
-      "pacific"
+      "pacific",
+      "nsclc"
     ],
     "or small-cell lung cancer": [
       "sclc"
     ],
     "sclc": [
+      "and small-cell lung cancer",
       "trial in small cell lung cancer",
-      "or small-cell lung cancer",
       "small cell lung cancer",
-      "and small-cell lung cancer"
+      "or small-cell lung cancer"
     ],
     "cancer": [
       "relay",
@@ -283,17 +283,17 @@
       "continued"
     ],
     "continued": [
-      "the bottom line",
-      "all recommendations"
+      "all recommendations",
+      "the bottom line"
     ],
     "salvage stereotactic body radiation therapy": [
       "sbrt"
     ],
     "sbrt": [
       "salvage stereotactic body radiation therapy",
+      "stereotactic body radiotherapy",
       "fdg-pet and stereotactic body radiotherapy",
-      "sabr or stereotactic body radiotherapy",
-      "stereotactic body radiotherapy"
+      "sabr or stereotactic body radiotherapy"
     ],
     "oncomed": [
       "inst"
@@ -320,9 +320,9 @@
       "alk"
     ],
     "alk": [
+      "crizotinib-pretreated anaplastic lymphoma kinase",
       "positive anaplastic lymphoma kinase",
-      "and anaplastic lymphoma kinase",
-      "crizotinib-pretreated anaplastic lymphoma kinase"
+      "and anaplastic lymphoma kinase"
     ],
     "immunohistochemistry": [
       "ihc"
@@ -332,12 +332,12 @@
       "immunohistochemistry"
     ],
     "merck": [
-      "german",
-      "inst"
+      "inst",
+      "german"
     ],
     "glaxosmithkline": [
-      "gsk",
-      "inst"
+      "inst",
+      "gsk"
     ],
     "astex pharmaceuticals": [
       "inst"
@@ -346,8 +346,8 @@
       "inst"
     ],
     "bristol myers\nsquibb": [
-      "bms",
-      "inst"
+      "inst",
+      "bms"
     ],
     "polaris": [
       "inst"
@@ -386,8 +386,8 @@
       "icis"
     ],
     "icis": [
-      "immune checkpoint inhibitors",
-      "neoadjuvant immune checkpoint inhibitors"
+      "neoadjuvant immune checkpoint inhibitors",
+      "immune checkpoint inhibitors"
     ],
     "american society of clinical oncology": [
       "asco"
@@ -408,12 +408,12 @@
       "inst"
     ],
     "bms": [
-      "celgene",
-      "bristol\nmyers squibb",
+      "bristol-myers\nsquibb",
       "bristol myers squibb",
       "inst",
       "bristol myers\nsquibb",
-      "bristol-myers\nsquibb"
+      "bristol\nmyers squibb",
+      "celgene"
     ],
     "trizell": [
       "inst"
@@ -431,30 +431,30 @@
       "rct"
     ],
     "rct": [
-      "a phase iii randomised clinical trial",
-      "one randomized controlled trial",
       "phase iii randomised clinical trial",
+      "one randomized controlled trial",
+      "a phase iii randomised clinical trial",
       "phase iib\nrandomised controlled trial"
     ],
     "the primary end point of progression-free survival": [
       "pfs"
     ],
     "pfs": [
-      "and\nprogression-free survival",
-      "the primary end point of progression-free survival",
+      "no\nimprovement in progression-free survival",
+      "the median\nprogression-free survival",
       "the median progression-free\nsurvival",
-      "reported improved\nprogression-free survival",
+      "the primary end point of progression-free survival",
       "quality of life and progression-free survival",
-      "no\nimprovement in progression-free survival",
-      "the median\nprogression-free survival"
+      "and\nprogression-free survival",
+      "reported improved\nprogression-free survival"
     ],
     "adverse events": [
       "aes"
     ],
     "aes": [
-      "mainly altered lipid levels",
+      "adverse events",
       "adverse\nevents",
-      "adverse events"
+      "mainly altered lipid levels"
     ],
     "and consolidation": [
       "for unresectable stage iii nsclc"
@@ -469,8 +469,8 @@
       "treatment is now an\negfr-targeted drug"
     ],
     "inc": [
-      "asco",
-      "inst"
+      "inst",
+      "asco"
     ],
     "small cell\nlung cancer": [
       "nsclc"
@@ -494,15 +494,15 @@
       "though rates of\nimmune-related aes"
     ],
     "bristol myers squibb": [
-      "bms",
-      "inst"
+      "inst",
+      "bms"
     ],
     "palobiofarma": [
       "inst"
     ],
     "dohme": [
-      "msd",
-      "inst"
+      "inst",
+      "msd"
     ],
     "mirati therapeutics": [
       "inst"
@@ -587,8 +587,8 @@
       "health research methods"
     ],
     "health research methods": [
-      "va asco practice guidelines staff",
-      "va asco practice guideline staff"
+      "va asco practice guideline staff",
+      "va asco practice guidelines staff"
     ],
     "in tyrosine kinase inhibitor": [
       "tki"
@@ -620,8 +620,8 @@
       "dor"
     ],
     "dor": [
-      "with a median duration of\nresponse",
-      "the median\nduration of response"
+      "the median\nduration of response",
+      "with a median duration of\nresponse"
     ],
     "the most common treatment-emergent adverse events": [
       "teaes"
@@ -648,8 +648,8 @@
       "inst"
     ],
     "msd": [
-      "inst",
-      "dohme"
+      "dohme",
+      "inst"
     ],
     "lilly": [
       "inst"
@@ -689,8 +689,8 @@
       "durvalumab"
     ],
     "durvalumab": [
-      "if ps improves\n\nv\n\nconsolidation immunotherapy",
-      "consolidation immunotherapy"
+      "consolidation immunotherapy",
+      "if ps improves\n\nv\n\nconsolidation immunotherapy"
     ],
     "if ps improves\n\nv\n\nconsolidation immunotherapy": [
       "durvalumab"
@@ -736,13 +736,13 @@
       "fda"
     ],
     "fda": [
+      "and the united states food and drug administration",
+      "and the food and drug administration",
       "entrectinib received food and\ndrug administration",
+      "the food and drug administration",
       "the us food and drug administration",
-      "and the food and drug administration",
       "or food and drug administration",
-      "and the united states food and drug administration",
-      "food and drug administration",
-      "the food and drug administration"
+      "food and drug administration"
     ],
     "cytokine release syndrome": [
       "crs"
@@ -791,8 +791,8 @@
       "seer"
     ],
     "seer": [
-      "epidemiology and end results",
-      "and end results"
+      "and end results",
+      "epidemiology and end results"
     ],
     "s syndrome": [
       "cus"
@@ -834,8 +834,8 @@
       "ssas"
     ],
     "ssas": [
-      "-labelled somatostatin analogues",
-      "medical options"
+      "medical options",
+      "-labelled somatostatin analogues"
     ],
     "urinary-free cortisol": [
       "ufc"
@@ -880,12 +880,12 @@
       "cht"
     ],
     "cht": [
+      "the beneficial effects of adjuvant chemotherapy",
       "platinum-based chemo\ntherapy",
-      "the addition of the chemotherapy",
+      "chemotherapy",
       "over platinum-based doublet\nchemotherapy",
       "mainly cytotoxic chemotherapy",
-      "the beneficial effects of adjuvant chemotherapy",
-      "chemotherapy"
+      "the addition of the chemotherapy"
     ],
     "or systemic therapies": [
       "with options\ndiscussed in these guidelines"
@@ -1015,12 +1015,12 @@
       "esmo-mcbs"
     ],
     "esmo-mcbs": [
+      "an esmo\nmagnitude of clinical benefit scale",
       "esmo-magnitude of\nclinical benefit",
-      "esmomagnitude of clinical benefit scale",
-      "esmo-magnitude of clinical benefit",
       "esmo-magnitude of clinical benefit scale",
       "esmo-magnitude of clinical\nbenefit",
-      "an esmo\nmagnitude of clinical benefit scale"
+      "esmomagnitude of clinical benefit scale",
+      "esmo-magnitude of clinical benefit"
     ],
     "advanced carcinoids of the lung and thymus": [
       "luna"
@@ -1074,8 +1074,8 @@
       "chuv"
     ],
     "chuv": [
-      "centre hospitalier universitaire\nvaudois",
-      "centre hospitalier universitaire vaudois"
+      "centre hospitalier universitaire vaudois",
+      "centre hospitalier universitaire\nvaudois"
     ],
     "comparing low-dose computed tomography": [
       "ldct"
@@ -1106,11 +1106,11 @@
       "who"
     ],
     "who": [
-      "the recent world health organization",
+      "global statistics",
       "vs universal",
       "global",
       "world health organization",
-      "global statistics"
+      "the recent world health organization"
     ],
     "with its further sub-classification of": [
       "surgically resected"
@@ -1164,8 +1164,8 @@
       "tnm"
     ],
     "tnm": [
-      "tumourenodeemetastasis",
-      "node and metastasis"
+      "node and metastasis",
+      "tumourenodeemetastasis"
     ],
     "proposed\nthat ais be classified as tis": [
       "ais"
@@ -1193,8 +1193,8 @@
       "accp"
     ],
     "accp": [
-      "whereas the american college of chest physicians",
-      "the\namerican college of chest physicians"
+      "the\namerican college of chest physicians",
+      "whereas the american college of chest physicians"
     ],
     "adjuvant chemotherapy": [
       "radiotherapy"
@@ -1269,9 +1269,9 @@
       "neo"
     ],
     "neo": [
+      "immunotherapy is being studied in early nsclc as",
       "the\nimmune strategy in the",
-      "- immunotherapy is being studied in early nsclc as",
-      "immunotherapy is being studied in early nsclc as"
+      "- immunotherapy is being studied in early nsclc as"
     ],
     "cl\n\ntreatment of locally advanced stage": [
       "stage ill"
@@ -1304,8 +1304,8 @@
       "ests"
     ],
     "ests": [
-      "and european society of thoracic surgeons",
-      "and the european\nsociety of thoracic surgeons"
+      "and the european\nsociety of thoracic surgeons",
+      "and european society of thoracic surgeons"
     ],
     "gv scagliotti": [
       "eds"
@@ -1327,8 +1327,8 @@
       "pulmonology"
     ],
     "pulmonology": [
-      "respiratory oncology unit",
-      "respiratory oncology"
+      "respiratory oncology",
+      "respiratory oncology unit"
     ],
     "edegem": [
       "antwerp"
@@ -1349,10 +1349,10 @@
       "stage iii"
     ],
     "stage iii": [
-      "unresectable nsclc",
       "locally advanced nsclc",
+      "and unresectable locally advanced",
       "treatment of locally advanced stage",
-      "and unresectable locally advanced"
+      "unresectable nsclc"
     ],
     "in paral\npractice guidelines": [
       "cpgs"
@@ -1407,8 +1407,8 @@
       "sub-lobar"
     ],
     "sub-lobar": [
-      "for which patients is limited",
-      "special articles\n\n\n\nfor which patients is limited"
+      "special articles\n\n\n\nfor which patients is limited",
+      "for which patients is limited"
     ],
     "especially those with ground-glass\nopacity": [
       "ggo"
@@ -1492,12 +1492,12 @@
       "pbc"
     ],
     "pbc": [
-      "five cycles of\n\ntremelimumab",
-      "platinum-based doublet chemotherapy"
+      "platinum-based doublet chemotherapy",
+      "five cycles of\n\ntremelimumab"
     ],
     "carboplatin": [
-      "arm a",
-      "arm b"
+      "arm b",
+      "arm a"
     ],
     "arm a": [
       "carboplatin"
@@ -1515,21 +1515,21 @@
       "primary endpoint"
     ],
     "primary endpoint": [
-      "level",
-      "significantly improved os",
+      "-year os",
       "pbc\nsignificantly improved pfs",
-      "-year os"
+      "significantly improved os",
+      "level"
     ],
     "besides immune checkpoint\n\ninhibitor": [
       "ici"
     ],
     "ici": [
-      "and have no prior immune checkpoint inhibitor",
-      "besides immune checkpoint\n\ninhibitor"
+      "besides immune checkpoint\n\ninhibitor",
+      "and have no prior immune checkpoint inhibitor"
     ],
     "esmo-magnitude of clinical benefit scale": [
-      "esmo-mcbs",
-      "mcbs"
+      "mcbs",
+      "esmo-mcbs"
     ],
     "mcbs": [
       "esmo-magnitude of clinical benefit scale"
@@ -1568,8 +1568,8 @@
       "esmo guidelines staff"
     ],
     "esmo guidelines staff": [
-      "jennifer\nlamarre and guy atchison",
-      "ioanna ntai and claire bramley"
+      "ioanna ntai and claire bramley",
+      "jennifer\nlamarre and guy atchison"
     ],
     "valerie laforest": [
       "esmo\nguidelines staff"
@@ -1581,8 +1581,8 @@
       "esmo scientific affairs staff"
     ],
     "esmo scientific affairs staff": [
-      "nicola\nlatino",
       "nicola latino and\nfrancesca chiovaro",
+      "nicola\nlatino",
       "nicola\nlatino and francesca chiovaro",
       "nicola latino"
     ],
@@ -1684,8 +1684,8 @@
       "uicc"
     ],
     "tumourenodeemetastasis": [
-      "tnm",
-      "staging and risk assessment\n\n\nthe tnm"
+      "staging and risk assessment\n\n\nthe tnm",
+      "tnm"
     ],
     "over platinum-based doublet\nchemotherapy": [
       "cht"
@@ -1794,9 +1794,9 @@
       "surgery or rt"
     ],
     "surgery or rt": [
+      "local treatment",
       "oligoprogression\n\nlocal treatment",
-      "disease progression\n\nlocal treatment",
-      "local treatment"
+      "disease progression\n\nlocal treatment"
     ],
     "or combination therapy with a mek inhibitor": [
       "trametinib"
@@ -1850,8 +1850,8 @@
       "high-dose rt or surgery"
     ],
     "high-dose rt or surgery": [
-      "from lat",
-      "may\nbenefit from lat"
+      "may\nbenefit from lat",
+      "from lat"
     ],
     "jennifer\nlamarre and guy atchison": [
       "esmo guidelines staff"
@@ -1970,8 +1970,8 @@
       "cancer"
     ],
     "non-small-cell lung cancer": [
-      "alesia",
-      "nsclc"
+      "nsclc",
+      "alesia"
     ],
     "alesia": [
       "non-small-cell lung cancer"
@@ -2030,8 +2030,8 @@
       "india"
     ],
     "jsmo": [
-      "japan",
-      "the\njapanese society of medical oncology"
+      "the\njapanese society of medical oncology",
+      "japan"
     ],
     "korea": [
       "ksmo"
@@ -2046,30 +2046,30 @@
       "psmo"
     ],
     "psmo": [
+      "the philippine society of\nmedical oncology",
       "and philippine society of medical\noncology",
-      "the philippines",
-      "the philippine society of\nmedical oncology"
+      "the philippines"
     ],
     "singapore": [
       "sso"
     ],
     "sso": [
-      "singapore",
-      "the singapore society of\noncology"
+      "the singapore society of\noncology",
+      "singapore"
     ],
     "taiwan": [
       "tos"
     ],
     "tos": [
-      "the taiwan oncology society",
-      "taiwan"
+      "taiwan",
+      "the taiwan oncology society"
     ],
     "and thailand": [
       "tsco"
     ],
     "tsco": [
-      "and thailand",
-      "and the\nthai society of clinical oncology"
+      "and the\nthai society of clinical oncology",
+      "and thailand"
     ],
     "and the neurotrophic receptor tyrosine\nkinase": [
       "ntrk"
@@ -2140,8 +2140,8 @@
       "such as osimertinib"
     ],
     "such as osimertinib": [
-      "generation tki",
-      "third-generation egfr tkis"
+      "third-generation egfr tkis",
+      "generation tki"
     ],
     "generation tki": [
       "such as osimertinib"
@@ -2315,8 +2315,8 @@
       "lond"
     ],
     "lond": [
-      "cancer commun",
-      "commun"
+      "commun",
+      "cancer commun"
     ],
     "mertinib": [
       "osi"
@@ -2328,8 +2328,8 @@
       "egfrm"
     ],
     "egfrm": [
-      "platinum-pemetrexed in egfr-mutated",
-      "with stage ibeiiia egfr mutation positive"
+      "with stage ibeiiia egfr mutation positive",
+      "platinum-pemetrexed in egfr-mutated"
     ],
     "advanced non-small cell lung cancer": [
       "nsclc"
@@ -2347,12 +2347,12 @@
       "pts"
     ],
     "pts": [
-      "p repotrectinib in patients",
-      "therapy in patients",
-      "patients",
       "mo encorafenib plus\n\nbinimetinib in patients",
+      "therapy in patients",
       "versus docetaxel in patients",
-      "binimetinib in patients"
+      "p repotrectinib in patients",
+      "binimetinib in patients",
+      "patients"
     ],
     "mutant advanced non-small cell lung cancer": [
       "nsclc"
@@ -2447,8 +2447,8 @@
       "pacific"
     ],
     "pacific": [
-      "concurrent chemoradiation therapy",
-      "small-cell lung cancer"
+      "small-cell lung cancer",
+      "concurrent chemoradiation therapy"
     ],
     "adaura": [
       "chemotherapy"
@@ -2499,8 +2499,8 @@
       "egfrm"
     ],
     "nivolumab": [
-      "nivo",
-      "bristol myers squibb statement on opdivo"
+      "bristol myers squibb statement on opdivo",
+      "nivo"
     ],
     "nivo": [
       "nivolumab"
@@ -2793,8 +2793,8 @@
       "esmo"
     ],
     "nice": [
-      "national institute for health and care excellence",
-      "nhs"
+      "nhs",
+      "national institute for health and care excellence"
     ],
     "national institute for health and care excellence": [
       "nice"
@@ -2871,35 +2871,35 @@
   },
   "abbreviations": {
     "esmo": [
-      "european society of medical oncology",
-      "european society for\nmedical oncology",
-      "the following european society for medical oncology",
+      "european\nsociety of medical oncology",
+      "the european society for medical oncology",
       "european society for medical\noncology",
+      "european society for medical oncology",
       "the most recent european society for medical oncology",
-      "the european society for medical oncology",
-      "european\nsociety of medical oncology",
-      "european society for medical oncology"
+      "european society for\nmedical oncology",
+      "the following european society for medical oncology",
+      "european society of medical oncology"
     ],
     "asco": [
+      "american society of clinical oncology",
+      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc",
       "american\nsociety of clinical oncology",
       "american society of clinical\n\noncology",
-      "american society of clinical\noncology",
-      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc",
       "this american society of clinical oncology",
-      "american society of clinical oncology"
+      "american society of clinical\noncology"
     ],
     "aiom": [
+      "the italian association of medical oncology",
       "italian association\nof medical oncology",
-      "italian association of medical oncology",
-      "the italian association of medical oncology"
+      "italian association of medical oncology"
     ],
     "nccn": [
-      "american cancer centers",
-      "national comprehensive cancer network"
+      "national comprehensive cancer network",
+      "american cancer centers"
     ],
     "glides": [
-      "guidelines into decision\nsupport",
-      "ecision support"
+      "ecision support",
+      "guidelines into decision\nsupport"
     ],
     "glc": [
       "guidelines committee"
@@ -2923,69 +2923,69 @@
       "executive summary of an american society for\nradiation oncology"
     ],
     "inst": [
-      "mirati therapeutics",
-      "genentech",
+      "sutro biopharma",
+      "amgen",
+      "roche",
       "merck",
-      "forward",
-      "bayer",
-      "revolution medicines",
-      "puma biotechnology",
-      "guardant health",
+      "constellation pharmaceuticals",
+      "nuvation bio",
+      "calithera biosciences",
+      "genentech",
+      "astex pharmaceuticals",
+      "merck serono",
+      "zeneca",
+      "kline",
+      "vivace therapeutics",
+      "heart therapeutics",
+      "novartis",
+      "elevation oncology",
+      "advaxis",
+      "summit therapeutics",
+      "takeda",
+      "blueprint medicines",
       "turning point therapeutics",
-      "trizell",
-      "exelixis",
-      "kline canada",
+      "janssen",
+      "genomics",
+      "pharmaceuticals",
       "immune",
-      "harpoon therapeutics",
-      "macrogenics",
-      "roche",
       "pfizer",
+      "polaris",
+      "exelixis",
+      "bristol myers squibb foundation",
+      "forward",
       "zeneca canada",
+      "mirati therapeutics",
+      "puma biotechnology",
+      "palobiofarma",
+      "harpoon therapeutics",
+      "kline canada",
       "cullinan oncology",
-      "pharmaceuticals",
-      "calithera biosciences",
-      "heart therapeutics",
-      "janssen oncology",
-      "dohme",
-      "bristol myers squibb foundation",
-      "jazz pharmaceuticals",
+      "trizell",
       "arcus biosciences",
-      "janssen",
-      "elevation oncology",
       "lilly",
-      "takeda",
-      "astra zeneca",
       "therapeutics",
-      "sutro biopharma",
-      "inhibrx",
-      "vivace therapeutics",
-      "genomics",
-      "regeneron",
-      "myers squibb",
-      "merck serono",
-      "palobiofarma",
       "boehringer ingelheim",
-      "constellation pharmaceuticals",
-      "astex pharmaceuticals",
-      "verastem",
+      "myers squibb",
+      "janssen oncology",
+      "jazz pharmaceuticals",
       "black diamond\ntherapeutics",
-      "summit therapeutics",
-      "amgen",
+      "astra zeneca",
       "dizal\npharma",
-      "novartis",
-      "zeneca",
-      "blueprint medicines",
-      "nuvation bio",
       "bristol myers squibb",
-      "advaxis",
-      "kline",
+      "dohme",
+      "regeneron",
+      "inhibrx",
+      "guardant health",
+      "verastem",
       "bristol myers\nsquibb",
-      "polaris"
+      "revolution medicines",
+      "macrogenics",
+      "bayer"
     ],
     "ct": [
-      "the use of\ncomputed tomography",
+      "clinicians should use a diagnostic chest computed tomography",
       "computed tomography",
-      "clinicians should use a diagnostic chest computed tomography"
+      "the use of\ncomputed tomography"
     ],
     "mri": [
       "what is the role of brain magnetic resonance imaging"
@@ -2998,12 +2998,12 @@
       "pathologists"
     ],
     "iaslc": [
-      "pathology committee chair\nfor international association for the study of lung cancer",
-      "international association for the\n\nstudy of lung cancer",
       "study of lung cancer",
       "international association for the\nstudy of lung cancer",
+      "international association for\nthe study of lung cancer",
       "the\ninternational association for the study of lung cancer",
-      "international association for\nthe study of lung cancer"
+      "pathology committee chair\nfor international association for the study of lung cancer",
+      "international association for the\n\nstudy of lung cancer"
     ],
     "amp": [
       "association\nfor molecular pathology"
@@ -3018,8 +3018,8 @@
       "although the results from the mesothelioma and radical surgery"
     ],
     "os": [
-      "overall survival",
-      "the median\noverall survival"
+      "the median\noverall survival",
+      "overall survival"
     ],
     "elsevier": [
       "clinical lung cancer"
@@ -3038,8 +3038,8 @@
       "prophylactic cranial irradiation"
     ],
     "fda": [
-      "entrectinib received food and\ndrug administration",
       "united states food and drug administration",
+      "entrectinib received food and\ndrug administration",
       "osimertinib is approved by both the united states food and\ndrug administration",
       "these results led to the food\n\nand drug administration",
       "food and drug administration"
@@ -3051,24 +3051,24 @@
       "department of surgical sciences"
     ],
     "who": [
-      "the recent world health organization",
+      "global statistics",
+      "the latest world health organization",
       "global",
       "world health organization",
-      "global statistics",
-      "the latest world health organization"
+      "the recent world health organization"
     ],
     "lc": [
       "these\nguidelines are restricted to lung carcinoid"
     ],
     "seer": [
-      "epidemiology and end results",
-      "end results"
+      "end results",
+      "epidemiology and end results"
     ],
     "uicc": [
-      "union for international cancer control",
       "edition of the union for\ninternational cancer control",
-      "union for international\ncancer control",
-      "union for\ninternational cancer control"
+      "union for\ninternational cancer control",
+      "union for international cancer control",
+      "union for international\ncancer control"
     ],
     "gep": [
       "based on\napproval and recommendations in gastroenteropancreatic"
@@ -3081,9 +3081,9 @@
       "for these patients radiofrequency ablation"
     ],
     "recist": [
-      "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours",
+      "cs with response evaluation criteria\nin solid tumours",
       "measurements and response assessment should follow response evaluation criteria in solid tumours",
-      "cs with response evaluation criteria\nin solid tumours"
+      "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours"
     ],
     "gemox": [
       "oxaliplatin combined with gemcitabine"
@@ -3092,12 +3092,12 @@
       "lanreotide autogel"
     ],
     "chuv": [
-      "centre hospitalier universitaire\nvaudois",
-      "centre hospitalier universitaire vaudois"
+      "centre hospitalier universitaire vaudois",
+      "centre hospitalier universitaire\nvaudois"
     ],
     "nlst": [
-      "national cancer institute\nannounced the results of the national lung cancer screening\ntrial",
-      "the much larger national lung cancer screening trial"
+      "the much larger national lung cancer screening trial",
+      "national cancer institute\nannounced the results of the national lung cancer screening\ntrial"
     ],
     "bts": [
       "guidelines developed by the british thoracic society"
@@ -3121,8 +3121,8 @@
       "for cases with mutation in epidermal growth factor receptor"
     ],
     "rtog": [
-      "data from a completed prospective\nradiation therapy oncology group",
-      "radiation therapy oncology group"
+      "radiation therapy oncology group",
+      "data from a completed prospective\nradiation therapy oncology group"
     ],
     "esge": [
       "european society of gastrointestinal endoscopy"
@@ -3139,8 +3139,8 @@
       "the thoracic surgery scoring\nsystem"
     ],
     "pulmonology": [
-      "respiratory oncology unit",
-      "respiratory oncology"
+      "respiratory oncology",
+      "respiratory oncology unit"
     ],
     "acs": [
       "lung cancer screening guidelines published by the\namerican cancer society"
@@ -3162,10 +3162,10 @@
       "bemeneed"
     ],
     "bms": [
+      "bristol\nmyers squibb",
       "myers\nsquibb",
       "bristol myers squibb",
-      "bristol myers\nsquibb",
-      "bristol\nmyers squibb"
+      "bristol myers\nsquibb"
     ],
     "msd": [
       "dohme"
@@ -3179,9 +3179,9 @@
       "clinical practice guideline"
     ],
     "escat": [
-      "targets",
+      "scale for clinical actionability of molecular targets",
       "scale for clinical actionability of\nmolecular targets",
-      "scale for clinical actionability of molecular targets"
+      "targets"
     ],
     "alk": [
       "positive anaplastic lymphoma kinase"
@@ -3228,9 +3228,9 @@
       "chinese lung\ncancer research foundation limited"
     ],
     "csco": [
-      "chinese society of clinical oncology",
+      "chinese\nsociety of clinical oncology",
       "china",
-      "chinese\nsociety of clinical oncology"
+      "chinese society of clinical oncology"
     ],
     "hkcf": [
       "hong kong cancer fund"
@@ -3251,8 +3251,8 @@
       "president of swiss\nacademy of multidisciplinary oncology"
     ],
     "sakk": [
-      "research",
-      "president of lung group for swiss group for clinical cancer\nresearch"
+      "president of lung group for swiss group for clinical cancer\nresearch",
+      "research"
     ],
     "etop": [
       "european thoracic oncology platform"
@@ -3270,8 +3270,8 @@
       "cancers"
     ],
     "chmp": [
-      "summary of opinion",
-      "products for human use"
+      "products for human use",
+      "summary of opinion"
     ],
     "paga": [
       "asian adapted"
@@ -3281,33 +3281,33 @@
       "indonesia"
     ],
     "jsmo": [
-      "japan",
-      "japanese society of medical oncology"
+      "japanese society of medical oncology",
+      "japan"
     ],
     "ksmo": [
-      "korean society for medical oncology",
-      "korea"
+      "korea",
+      "korean society for medical oncology"
     ],
     "mos": [
-      "malaysian oncological society",
-      "malaysia"
+      "malaysia",
+      "malaysian oncological society"
     ],
     "psmo": [
       "philippine society of\nmedical oncology",
-      "philippine society of medical\noncology",
-      "philippines"
+      "philippines",
+      "philippine society of medical\noncology"
     ],
     "sso": [
-      "singapore",
-      "singapore society of\noncology"
+      "singapore society of\noncology",
+      "singapore"
     ],
     "tos": [
-      "taiwan oncology society",
-      "taiwan"
+      "taiwan",
+      "taiwan oncology society"
     ],
     "tsco": [
-      "thailand",
-      "thai society of clinical oncology"
+      "thai society of clinical oncology",
+      "thailand"
     ],
     "ismpo": [
       "indian\nsociety of medical and paediatric oncology"
@@ -3350,8 +3350,8 @@
       "ireland oesophagogastric group"
     ],
     "lond": [
-      "cancer commun",
-      "commun"
+      "commun",
+      "cancer commun"
     ],
     "nivo": [
       "nivolumab"